Differential Expression of Circulating miRNAs and Carfilzomib-Related Cardiovascular Adverse Events in Patients with Multiple Myeloma
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25147795 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Marwa Tantawy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Oligopeptides, Circulating MicroRNA, Cardiovascular Diseases. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Florida College of Pharmacy.
Themen: Patientensicherheit
Abstract (Originalsprache)
This study investigates the association between circulating microRNA (miRNA) expression and cardiovascular adverse events (CVAE) in multiple myeloma (MM) patients treated with a carfilzomib (CFZ)-based regimen. A cohort of 60 MM patients from the Prospective Observation of Cardiac Safety with Proteasome Inhibitor (PROTECT) study was analyzed. Among these, 31 patients (51.6%) developed CVAE post-CFZ treatment. The Taqman OpenArray Human microRNA panels were used for miRNA profiling. We identified 13 differentially expressed miRNAs at baseline, with higher expressions of miR-125a-5p, miR-15a-5p, miR-18a-3p, and miR-152-3p and lower expression of miR-140-3p in patients who later developed CVAE compared to those free of CVAE, adjusting for age, gender, race, and higher B-type natriuretic peptide levels. We also identified three miRNAs, including miR-150-5p, that were differentially expressed in patients with and without CVAE post-treatment. Additionally, five miRNAs responded differently to CFZ treatment in CVAE vs. non-CVAE patients, including significantly elevated post-treatment expression of miR-140-3p and lower expressions of miR-598, miR-152, miR-21, and miR-323a in CVAE patients. Pathway enrichment analysis highlighted the involvement of these miRNAs in cardiovascular diseases and vascular processes. These findings suggest that specific miRNAs could serve as predictive biomarkers for CVAE and provide insights into the underlying mechanisms of CFZ-CVAE. Further investigation is warranted before these findings can be applied in clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.
- Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.
- Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
- Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
- Cape Cardiology Group, Saint Francis Medical Center, Cape Girardeau, MO 63703, USA.
- Thalheimer Center for Cardio-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
ORCID-Profile: Marwa Tantawy, Danxin Wang, Daniel Lenihan, Yan Gong
Förderung
- University of Florida College of Pharmacy
Zitieren
APA
Tantawy, M., Langaee, T., Wang, D., Rubinstein, S. M., Cornell, R. F., Lenihan, D., Fradley, M. G., & Gong, Y. (2024). Differential Expression of Circulating miRNAs and Carfilzomib-Related Cardiovascular Adverse Events in Patients with Multiple Myeloma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25147795
Vancouver
Tantawy M, Langaee T, Wang D, Rubinstein SM, Cornell RF, Lenihan D, et al. Differential Expression of Circulating miRNAs and Carfilzomib-Related Cardiovascular Adverse Events in Patients with Multiple Myeloma. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25147795
BibTeX
@article{Tantawy2024,
author = {Tantawy, Marwa and Langaee, Taimour and Wang, Danxin and Rubinstein, Samuel M and Cornell, Robert F and Lenihan, Daniel and Fradley, Michael G and Gong, Yan},
title = {Differential Expression of Circulating miRNAs and Carfilzomib-Related Cardiovascular Adverse Events in Patients with Multiple Myeloma},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25147795}
}
EUVIMED